Business Context and Reporting Period
This Form 6-K filing by Sanofi covers the month of September 2017. The report serves to incorporate by reference two press releases issued in early September 2017 regarding specific developments in the company's pipeline and alliance partnerships.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory notice referencing press releases and does not contain financial statements or quantitative performance data.
Material Changes and Developments
- Cemiplimab (REGN2810): On September 8, 2017, Sanofi and Regeneron announced that Cemiplimab received FDA Breakthrough Therapy Designation for the treatment of advanced cutaneous squamous cell carcinoma.
- Fitusiran Update: On September 7, 2017, Sanofi's alliance partner, Alnylam, provided an update on the development program for Fitusiran.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, management outlook, specific risk factors, or contingencies beyond the general context of the referenced press releases. No unusual items or financial adjustments are detailed in this specific document.
Investor Verification Checklist
- Verify the full details of the FDA Breakthrough Therapy Designation for Cemiplimab in the attached Exhibit 99.1.
- Review the specific clinical or regulatory updates regarding Fitusiran provided by Alnylam in Exhibit 99.2.
- Confirm the status of the Sanofi-Regeneron and Sanofi-Alnylam alliances as described in the referenced press releases.